In Silico Trial of MR-Guided Mid-Treatment Adaptive Planning for Hypofractionated Stereotactic Radiotherapy in Centrally Located Thoracic Tumors

In this in silico trial, central thorax tumor response to hypofractionated stereotactic radiotherapy (HSRT) was defined using prospective daily MRI. We then investigated whether tumor response could be used advantageously to reduce dose to organs-at-risk while preserving target coverage. We found that mid-treatment adaptive planning based on observed significant tumor response improved organ-at-risk sparing and target coverage. Our findings suggest online adaptive planning using MRI-guided radiation could improve the therapeutic index of central thoracic radiotherapy.

https://ift.tt/2IsL5sj